Hypothesis\nChronic use of NSAIDs blunt the prostaglandin‑EP1/EP4 axis that normally drives sustained release of CGRP and substance P from nociceptors, thereby muting a damage‑signal that triggers p53‑mediated senescence clearance and cardioprotective pathways. We propose that long‑term NSAID exposure leads to a dual hit: (1) reduced neuropeptide‑mediated senolytic signaling, allowing senescent cells to persist in the vasculature and heart; (2) loss of CGRP‑driven vasodilatory and bone‑protective effects, amplifying inflammation and fibrosis. This predicts that individuals with high cumulative NSAID intake will show (a) elevated circulating senescence markers (p16^INK4a^, SASP cytokines) and (b) increased cardiovascular morbidity independent of baseline pain levels.\n\n## Testable Predictions\n- In a cohort of middle‑aged adults, high NSAID burden (≥500 defined daily doses/year) will correlate with higher plasma levels of senescence‑associated secretory phenotype (SASP) factors (IL‑6, MMP‑9) after adjusting for pain scores, comorbidities, and socioeconomic status (linear regression, p<0.01).\n- Randomized crossover trial: participants receiving a short‑course NSAID (ibuprofen 600 mg TID for 2 weeks) will exhibit a transient ↓ in circulating CGRP and substance P (ELISA) and a concomitant ↑ in plasma p16^INK4a^‑positive extracellular vesicles compared with acetaminophen control (paired t‑test, p<0.05).\n- In aged mice, chronic NSAID treatment (celecoxib 30 mg/kg diet) will increase aortic senescent cell burden (p21^Cip1^ immunostaining) and exacerbate angiotensin‑II‑induced fibrosis, effects rescued by co‑administration of a senolytic (dasatinib + quercetin) or exogenous CGRP peptide (p<0.01 vs NSAID alone).\n\n## Mechanistic Insight Beyond Cited Work\nProstaglandin‑EP1/EP4 signaling not only sensitizes nociceptors but also activates a feedback loop whereby CGRP released from sensory axons engages endothelial CGRP receptors (CLR/RAMP1) to stimulate nitric oxide production and inhibit NF‑κB‑driven SASP. NSAID‑induced prostaglandin blockade therefore silences both the alarm (pain) and the repair signal (CGRP‑NO axis). This dual silencing creates a permissive environment for mitochondrial‑damage‑induced senescent cells to accumulate, particularly in tissues with high mechanical load (vasculature, intervertebral disc). It's unclear whether androgen‑dependent up‑regulation of COX‑2 in dorsal horn neurons amplifies the prostaglandin‑CGRP axis in males, making them more reliant on this pathway for damage surveillance; thus pharmacological blockade hits males harder. We can't ignore that the male‑specific mortality signal observed in epidemiologic data may stem from this heightened reliance.\n\n## Falsifiability\nIf longitudinal studies find no association between NSAID burden and senescence markers after controlling for pain, or if NSAID administration fails to reduce CGRP/substance P and does not increase senescence biomarkers, the hypothesis is refuted. Conversely, demonstrating that senolytic or CGRP replacement mitigates NSAID‑driven cardiovascular pathology would strongly support the mechanistic chain.\n\n## References (inline)\n[1] Chronic neuropathic pain triggers p53‑mediated senescence in mouse spinal cord https://www.jci.org/articles/view/166949\n[2] Pain interference predicts mortality HR 1.39 per SD at age 60 https://pubmed.ncbi.nlm.nih.gov/37771419/\n[3] PGE2 drives substance P and CGRP via EP1/EP4 https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1471-4159.2010.06927.x\n[4] CGRP decline with age and cardiovascular risk of antagonists https://www.medcentral.com/neurology/migraine/stake-possible-long-term-side-effects-cgrp-antagonists\n[5] Substance P and CGRP drop in aging rat spinal cord and synovium https://pubmed.ncbi.nlm.nih.gov/11985877/